MedTrace Logo

Phase II Study of Adenovirus/PSA Vaccine in Men With Hormone - Refractory Prostate Cancer

NCT00583024 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2023-04-28

Study results available
· View outcomes & findings →

Summary

This investigational study involves treatment with an Ad/PSA vaccine for men with prostate cancer who present with evidence of hormone refractory metastatic disease.

Conditions

  • Hormone Refractory Prostate Cancer

Interventions

BIOLOGICAL

ADENOVIRUS/PSA VACCINE

1x10E8 pfu in Gelfoam subcutaneously on days 0, 30, 60

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • David M Lubaroff

    lead OTHER

Principal Investigators

  • David M Lubaroff, PhD · University of Iowa

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2020-12-31
Completion
2023-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00583024 on ClinicalTrials.gov